Drug and diet interactions: Avoiding therapeutic paralysis

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 16, 1998, Pages 31-39

  Jefferson, James W ^a  

^a Madison Institute of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ASTEMIZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CISAPRIDE; CITALOPRAM; CLOMIPRAMINE; CYCLOSPORIN; CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOTHANE; KETOCONAZOLE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORSERTRALINE; PAROXETINE; PROPRANOLOL; QUINIDINE; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

DEPRESSION; DRUG EFFICACY; DRUG METABOLISM; DRUG MIXTURE; DRUG SAFETY; DRUG SELECTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SPECIFICITY; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; GRAPE; PRIORITY JOURNAL; REVIEW; VEGETARIAN DIET;

ANTIDEPRESSIVE AGENTS; BEVERAGES; CITRUS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; FOOD-DRUG INTERACTIONS; HUMANS; INFANT; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS;

EID: 0031717858     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Pantuck EJ, Pantuck CB, Garland WA, et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979;25:88-95
2. Conney AH, Pantuck EJ, Hsiao KC, et al. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 1976;20:633-642
3. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997;32:103-121
4. Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997;61:395-400
5. Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996;59:383-388
6. Roller L. Drugs and grapefruit juice. Clin Pharmacol Ther 1998;63:87-88
7. Chan WK, Nguyen LT, Miller VP, et al. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998;62:135-142
8. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics, the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 1996:3-27
9. Waxman DJ, Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 1992;281:577-592
10. Cashman JR. Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem Res Toxicol 1995;8:165-181
11. Larkin M. Fishy odour found in the genes. Lancet 1997;350:1684
12. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:513-580
13. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997;43:7-35
14. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995;68:385-424
15. Nelson DR, Koymans L, Kamatiki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42
16. Lieber CS. Medical disorders of alcoholism. N Engl J Med 1995;333:1058-1065
17. Mitchell SC, Waring RH, Land D, et al. Odorous urine following asparagus ingestion in man. Experientia 1987;43:382-383
18. Smith RL. Polymorphism in drug metabolism - implications for drug toxicity. Arch Toxicol 1986;9:138-146
19. Waring RH, Mitchell SC, Fenwick GR. The chemical nature of the urinary odour produced by man after asparagus ingestion. Xenobiotica 1987;17:1363-1371
20. Lison M, Blondheim SH, Melmed RN. A polymorphism of the ability to smell urinary metabolites of asparagus. BMJ 1980;281:1676-1678
21. Mitchell SC. Asparagus and malodorous urine. Br J Clin Pharmacol 1989;27:641-642
22. Richer C, Decker N, Belin J, et al. Odorous urine in man after asparagus. Br J Clin Pharmacol 1989;27:640-641
23. Jefferson JW, Greist JH. Brussels sprouts and psychopharmacology: understanding the cytochrome P450 system. In: Jefferson JW, Greist JH, eds. Psychiatric Clinics of North America: Annual of Drug Therapy. Philadelphia, PA: WB Saunders Co; 1996;3:205-222
24. Jefferson JW. Drug interactions - friend or foe? J Clin Psychiatry 1998; 59(suppl 4):37-47
25. Poulsen L, Brøsen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetic, analgesic effect and side effects. Eur J Clin Pharmacol 1996;51:289-295
26. Dalén P, Frengell C, Dahl M-L, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997;19:543-544
27. Yue QY, Aim C, Svensson JO, et al. Quantification of the O- and the N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid and poor debrisoquine hydroxylators. Ther Drug Monit 1997;19:539-542
28. Tyndale RF, Droll KR, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997;7:375-379
29. Eaton DL, Gallagher EP, Bammler TK, et al. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 1995;5:259-274
30. Kostrubsky VE, Strom SC, Wood SG, et al. Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch Biochem Biophys 1995;322:516-520
31. Lundahl J, Regårdh CG, Edgar B, et al. The grapefruit juice interaction with felodipine - does it change over a 14-day treatment period? [abstract] Clin Pharmacol Ther 1998;62:158
32. Rankin AC. Non-sedating antihistamines and cardiac arrhythmia. Lancet 1997;350:1115-1116
33. Villikka K, Kivistö KT, Backman JT, et al. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997;61:8-14
34. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-607
35. Halcion [package insert]. Kalamazoo, MI: The Upjohn Company: 1996
36. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997;72:835-847
37. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors, part I. J Clin Psychopharmacol 1996;16:273-285
38. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors, part II. J Clin Psychopharmacol 1996;16: 345-355
39. Ereshefsky L, Alfaro CL, Lam YWF. Treating depression: potential drug interactions. Psychiatr Ann 1997;27:244-258
40. Sproule BA, Naranjo CA, Bremner KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. Clin Pharmacokinet 1997;33:454-471
41. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-469
42. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320
43. Steffens DC, Krishnan KRR, Doraiswamy PM. Psychotropic drug interactions. Primary Psychiatry 1997;4:24-53
44. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-258
45. von Moltke LL, Greenblatt DJ, Fogelman SM, et al. Citalopram and desmethylcitalopram in vitro. Poster presented at the 36th annual meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Waikoloa, Hawaii
46. Gram LF, Hansen MGJ, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993;15:18-24
47. Priskorn M, Sidhu JS, Larsen F, et al. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997;44:199-202
48. Rochat B, Amey M, Gillet M, et al. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997;7:1-10
49. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997;280:927-933
50. Preskom SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-98
51. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1997;32:1-21
52. von Moltke LL, Greenblatt DJ, Duan SX, et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology (Berl) 1997;132:402-407
53. Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996;60:512-521
54. Aspeslet LJ, Baker GB, Coutts RT, et al. The effects of desipramine and iprindole on levels of enantiomers of fluoxetine in rat brain and urine. Chirality 1994;6:86-90
55. Koponen HJ, Leinonen E, Lepola U. Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 1996;6:69-71
56. DeVane CL, Markowitz JS, Hardesty SJ, et al. Fluvoxamine-induced theophylline toxicity. Am J Psychiatry 1997;154:1317-1318
57. Jeppesen U, Loft S, Poulsen HE, et al. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-222
58. Luvox [package insert]. Marietta, GA: Solvay Pharmaceuticals, Inc; 1997
59. Conus P, Bondolfi G, Eap CB, et al. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry 1996;29:108-110
60. Szegedi A, Wetzel H, Leal M, et al. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry 1996;57:257-264
61. Carrillo JA, Dahl M-L, Svensson JO, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-190
62. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-78
63. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-291
64. Özdemir V, Naranjo CA, Hermann N, et al. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997;62:334-347
65. Sproule BA, Otton SV, Cheung SW, et al. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997;17:102-106
66. Solai LK, Mulsant BH, Pollock BG, et al. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 1997;58:440-443
67. Zoloft [package insert]. New York, NY: Pfizer Inc; 1997
68. Özdemir V, Naranjo CA, Hermann N, et al. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. J Clin Psychopharmacol 1998;18:55-61
69. Preskorn SH, Alderman J, Greenblatt DJ, et al. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 1997;33:659-665
70. Haselberger MB, Freedman LS, Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol 1997;17:107-109
71. Shad MU, Preskorn SH. A possible bupropion and imipramine interaction. J Clin Psychopharmacol 1997;17:118-119
72. Wellbutrin [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 1997
73. Ekins S, VandenBranden M, Ring BJ, et al. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997;7:165-179
74. Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;15:327-333
75. Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997;37:737-743
76. Preskom SH. Should bupropion dosage be adjusted based upon therapeutic drug monitoring? Psychopharmacol Bull 1991;27:637-643
77. Pollock BG, Sweet RA, Kirshner M, et al. Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit 1996;18:581-585
78. Ball SE, Ahern D, Scatina J, et al. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997;43:619-626
79. von Moltke LL, Duan SX, Greenblatt DJ, et al. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. Biol Psychiatry 1997;41:377-380
80. Venlafaxine [package insert]. Philadelphia, Pa: Wyeth-Ayerst Laboratories; 1997
81. Albers LJ, Reist C, Helmeste DM, et al. Pharmacokinetic effects of venlafaxine on imipramine metabolism. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 20, 1997; San Diego, Calif. Abstract NR281:143
82. Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-156
83. Preskorn SH, Magnus RD, Horst D, et al. Pharmacokinetic and pharmacodynamic effects of co-administration of nefazodone and desipramine to normal volunteers. In: New Research Program and Abstracts of the 149th Annual Meeting of the American Psychiatric Association; May 7, 1996; New York, NY. Abstract NR195:120
84. Salazar DE, Dockens RC, Milbrath RL, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995;35:730-738
85. Nefazodone [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 1994
86. Ketter TA, Callahan AM, Post RM. Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition [letter]. J Clin Psychiatry 1996;57:307
87. Ashton AD, Wolin RE. Nefazodone-induced carbamazepine toxicity [letter]. Am J Psychiatry 1996;153:733
88. Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone [letter]. JAMA 1997;277:296
89. Helms-Smith KM, Curtis SL, Hatton RC. Apparent interaction between nefazodone and cyclosporine [letter]. Ann Intern Med 1996;125:424
90. Preskorn SH. Psychotropic drug interactions: a case for clinical significance: part I of an interview with Sheldon H. Preskorn, M.D. Curr Affect Illness 1998;17:5-13
91. Delbressine LPC, Vos RME. The clinical relevance of preclinical data: mirtazapine, a model compound. J Clin Psychopharmacol 1997;17(suppl 1):29-33
92. Dahl M-L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 1997;13:37-46
93. Delbressine LPC, Moonen MEG, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest 1998;15:45-55
94. Gram LF, Brøsen K. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 1993;35:649-652
95. Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995;57:670-677
96. König F, Wolfersdorf M, Löble M, et al. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression. Pharmacopsychiatry 1997;30:125-127